Stay updated with breaking news from Refractory gout. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Combining two medications doubles gout treatment success, study reveals By combining two medications, researchers at Michigan Medicine optimized a therapy for people with gout, a condition that causes severe damage and disability if left untreated. The study revealed how a second drug taken orally more than doubled the effectiveness of Pegloticase, an intravenous gout treatment used to dissolve crystalized uric acid in the joints when oral medications fail. Gout is a challenging disease to treat because there are only a handful of oral therapies to lower uric acid. Now, we have a medication that works and gives us a better chance to help people who have been suffering from gout for decades. ....
(0) Primary study endpoint demonstrates 86 percent response rate for patients receiving co-therapy of KRYSTEXXA and mycophenolate mofetil Horizon Therapeutics plc (Nasdaq: HZNP) announced the publication of data from the first randomized controlled clinical trial (RCT) of KRYSTEXXA (pegloticase injection) concomitantly used with an immunomodulator, mycophenolate mofetil, in Arthritis Rheumatology [doi.org/10.1002/art.41731]. The Reducing Immunogenicity of Pegloticase (RECIPE) trial demonstrated that 86 percent of patients (19 of 22) receiving co-therapy of KRYSTEXXA with the immunomodulator mycophenolate mofetil achieved serum uric acid (sUA) 6 mg/dL at 12 weeks, the primary study endpoint, compared to 40 percent of patients (4 of 10) receiving KRYSTEXXA monotherapy. The safety and efficacy of KRYSTEXXA co-prescribed with mycophenolate mofetil has not been established by any health authorities. ....